Published in PLoS One on October 03, 2012
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24
microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget (2014) 1.22
MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res (2014) 1.05
DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation. Mol Cell Biol (2013) 1.01
microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. Exp Ther Med (2014) 1.00
MicroRNAs in colorectal cancer as markers and targets: Recent advances. World J Gastroenterol (2014) 0.98
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget (2016) 0.94
Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression. Oncogene (2015) 0.93
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol (2014) 0.93
MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling. Oncotarget (2016) 0.90
Circulating cell-free microRNAs as biomarkers for colorectal cancer. Surg Today (2015) 0.88
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res (2013) 0.88
Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients. Diagn Pathol (2014) 0.87
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut (2015) 0.86
MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma. Exp Ther Med (2014) 0.84
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget (2016) 0.83
Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res (2014) 0.83
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget (2015) 0.83
Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci (2013) 0.82
Retracted MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther (2014) 0.82
miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Mol Ther (2015) 0.82
A two-microRNA signature as a potential biomarker for early gastric cancer. Oncol Lett (2014) 0.82
Decreased miR-198 expression and its prognostic significance in human gastric cancer. World J Surg Oncol (2016) 0.81
The Role of Mir-148a in Cancer. J Cancer (2016) 0.80
Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol (2015) 0.80
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach. Future Oncol (2015) 0.79
Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers. Onco Targets Ther (2014) 0.79
Down-Regulation of miR-148a Promotes Metastasis by DNA Methylation and is Associated with Prognosis of Skin Cancer by Targeting TGIF2. Med Sci Monit (2015) 0.77
MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer (2015) 0.76
Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer. Oncol Lett (2017) 0.75
miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. PLoS One (2017) 0.75
MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3'-untranslated region and alters the expression of its target gene cytochrome P450 3A4. Biochim Biophys Acta (2016) 0.75
piR-651 and its function in 95-D lung cancer cells. Biomed Rep (2016) 0.75
microRNAs Make the Call in Cancer Personalized Medicine. Front Cell Dev Biol (2017) 0.75
Milk's Role as an Epigenetic Regulator in Health and Disease. Diseases (2017) 0.75
MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) (2017) 0.75
miR-148a Suppresses estrogen-induced viability and migration of breast cancer cells via inhibition of estrogen receptor α expression. Exp Ther Med (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer (2006) 6.39
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
miR-148 targets human DNMT3b protein coding region. RNA (2008) 4.56
Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res (2008) 4.20
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol (2008) 3.18
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol (2010) 2.63
Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer (2009) 2.62
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer (2010) 2.10
MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer (2011) 1.89
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem (2008) 1.84
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem (2010) 1.66
MicroRNA expression profiling in classic Hodgkin lymphoma. Blood (2007) 1.64
Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg (2010) 1.63
MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res (2010) 1.49
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer (2009) 1.45
Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics (2011) 1.35
MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ (2011) 1.33
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest (2011) 1.30
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg (2011) 1.14
A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer (2011) 0.96
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet (2002) 14.34
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med (2012) 7.18
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg (2008) 5.94
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology (2004) 4.03
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res (2009) 3.44
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc (2011) 2.96
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Lynch syndrome: form, function, proteins, and basketball. Gastroenterology (2005) 2.57
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol (2005) 2.48
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A (2011) 2.45
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci (2012) 2.12
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn (2006) 2.11
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer (2008) 2.08
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg (2015) 2.06
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology (2002) 2.04
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol (2009) 1.89
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage. Gastrointest Endosc (2008) 1.82
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology (2007) 1.82
Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol (2004) 1.81
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol (2007) 1.73
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol (2002) 1.71
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A (2006) 1.70
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst (2007) 1.70
Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology (2012) 1.66
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology (2013) 1.55
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46
Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial. Gastroenterology (2008) 1.46
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol (2007) 1.44
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer (2005) 1.42
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41
Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet (2008) 1.40
MLH1 germ-line epimutations: is there strong evidence of its inheritance? Gastroenterology (2007) 1.40
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther (2011) 1.40